After inking a series of partnerships late last year, Lonza’s antibody-drug conjugate (ADC) specialist Synaffix is kicking off 2025 with a return to the dealmaking table. Under a new licensing pact, ...
Mere days after announcing that trials for its lead IL-15 asset have been halted over poor data, Sotio Biotech has unveiled plans to delve deeper into antibody-drug conjugates (ADCs) courtesy of deal ...
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual ...
The biotech industry has certainly hit the ground running in 2026. In its first edition of the year, the biotech bi-weekly highlights new products that can visualize multimodal biological data at ...
Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...
Poster Presentations featuring the latest advancements on anti-TROP2 (OBI 902) and Nectin-4 (OBI 904) ADCs, anti-TROP2/HER2 BsADC (OBI 201), anti-cMET/HER3Bs-Dual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results